share_log

Needham Reiterates Buy on Autolus Therapeutics, Maintains $9 Price Target

Benzinga ·  Jun 17 17:52

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment